Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

971.09 -32.49 (-3.24%)

Streaming Delayed Price Updated: 2:26 PM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

99 100 Next >

Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report ↗

January 30, 2026

CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk.

Via Stocktwits

Topics Government

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? ↗

January 30, 2026

Novo Nordisk's weight loss pill could give the company's numbers a big boost this year.

Via The Motley Fool

Stock Yards Bank Buys $25 Million of Stock Yards Bancorp Stock ↗

January 30, 2026

Stock Yards Bancorp delivers commercial banking and wealth management services across key Midwest metropolitan markets.

Via The Motley Fool

Topics Regulatory Compliance

Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases ↗

January 30, 2026

Novo Nordisk sharply increased U.S. advertising for Wegovy and Ozempic in 2025, outspending Eli Lilly as competition for obesity drugs intensified.

Via Benzinga

Eli Lilly & Co (NYSE:LLY) Emerges as a Top GARP Investment Candidate ↗

January 30, 2026

Via Chartmill

FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock? ↗

January 30, 2026

The target action date for orforglipron is now April 10.

Via The Motley Fool

Should You Buy Eli Lilly Before Feb. 4? ↗

January 30, 2026

Is there another beat-and-raise in the pharmaceutical giant's near future?

Via The Motley Fool

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

This genomics stock appears to be at an inflection point.

Via The Motley Fool

Topics Earnings

Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion ↗

January 29, 2026

Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease treatments and gene therapies targeting hearing loss.

Via Benzinga

How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity ↗

January 29, 2026

Roche hopes to rival Eli Lilly and Novo Nordisk in the weight-loss space.

Via Investor's Business Daily

Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead. ↗

January 29, 2026

This pharmaceutical giant is increasingly looking unstoppable.

Via The Motley Fool

Topics Artificial Intelligence

Can This Beaten-Down AI Stock Bounce Back in 2026? ↗

January 28, 2026

It might take a while for this AI company to prove its worth, if it ever does so.

Via The Motley Fool

Topics Artificial Intelligence

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. ↗

January 28, 2026

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Via The Motley Fool

FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency

January 28, 2026

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial...

Via TokenRing AI

Topics Artificial Intelligence Economy

The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life

January 28, 2026

In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic...

Via TokenRing AI

Topics Artificial Intelligence Economy

Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences

January 28, 2026

In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire...

Via MarketMinute

Eli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing Loss ↗

January 28, 2026

Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss.

Via Stocktwits

Topics Economy Government

Top Picks 2026: Eli Lilly & Co. ↗

January 27, 2026

LLY is surging as its weight-loss duopoly remains a 2026

Via Talk Markets

The Master Architect of Molecules: How Google DeepMind’s AlphaProteo is Rewriting the Blueprint for Cancer Therapy

January 27, 2026

In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a...

Via TokenRing AI

Topics Artificial Intelligence

Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 27, 2026

In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx...

Via MarketMinute

1 Pharmaceutical Stock Set to Rebound in 2026 ↗

January 27, 2026

Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.

Via The Motley Fool

Carvina Capital: Strong Demand Lifts Aktis IPO

January 27, 2026

Via AB Newswire

Up 36%, Is Eli Lilly Still a Buy? ↗

January 27, 2026

Thanks to its weight loss and diabetes products, the drug company has seen its shares soar.

Via The Motley Fool

Where Will Eli Lilly Be in 10 Years? ↗

January 27, 2026

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Via The Motley Fool

Topics ETFs Intellectual Property

2 Profitable Stocks to Own for Decades and 1 Facing Headwinds

January 26, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack

January 26, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Ocular Therapeutix...

Via StockStory

Topics Artificial Intelligence Intellectual Property

The Silicon Laureates: How the 2024 Nobel Prizes Rewrote the Rules of Scientific Discovery

January 26, 2026

The year 2024 marked a historic inflection point in the history of science, as the Royal Swedish Academy of Sciences awarded Nobel Prizes in both Physics and Chemistry to pioneers of artificial...

Via TokenRing AI

Topics Artificial Intelligence

Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗

January 26, 2026

Both companies may succeed in this industry.

Via The Motley Fool

A Look Into Eli Lilly and Co Inc's Price Over Earnings ↗

January 26, 2026

Via Benzinga

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.